– USA, MA – Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells for the treatment of cancer, today announced the appointment of Daniella Beckman to its Board of Directors. .
“Daniella is a fantastic addition to our Board of Directors and we are honored to have her join at this important time for our company,” said CEO, Robert Ang. “Her expertise in financial strategy and operations will be of great value to us as we leverage our recent Series B funding round to further advance our lead product candidate VOR33 towards clinical trials and continue to build out our portfolio.”
The appointment of Ms. Beckman, an experienced biotech finance leader who currently serves as CFO at Tango Therapeutics, follows the hiring of Christopher Slapak, MD, as Chief Medical Officer and the completion of a $110 million Series B financing round
About Daniella Beckman
Ms. Beckman joins Vor with deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career. At Tango Therapeutics, Ms. Beckman oversees finance, investor relations, and business development. Prior to joining Tango, Ms. Beckman was a consultant to early-stage biotechnology companies, leading financial activities and building companies’ financial infrastructures. She also served as Interim CFO for Neon Therapeutics. Previously, Ms. Beckman was CFO of Idenix Pharmaceuticals, where she was responsible for finance, investor relations, and IT until the company was acquired by Merck in 2014. Earlier in her career, she held various finance positions at Coley Pharmaceuticals, Biogen Idec, and PricewaterhouseCoopers.
“The Series B financing is testament to the potential for eHSCs to improve the treatment paradigm for patients with blood cancers such as acute myeloid leukemia,” Ms. Beckman said. “I am looking forward to working with and supporting Vor as the company continues to innovate to address cancer patients in need.”
Ms. Beckman received her BA in business administration and accounting from Boston University and is a Certified Public Accountant in Massachusetts.
Ms. Beckman also serves on the Board of Directors of Translate Bio as Chair of the Audit and the Nomination and Governance Committees.
About Vor Biopharma
Vor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell therapies. By removing biologically redundant proteins from eHSCs, these cells become inherently invulnerable to complementary targeted therapies while tumor cells are left susceptible, thereby unleashing the potential of targeted therapies to benefit cancer patients in need.
Vor’s platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody-drug conjugates, bispecific antibodies and CAR-T cell treatments.
Vor is based in Cambridge, Mass. and has a broad intellectual property base, including in-licenses from Columbia University, where foundational work was conducted by inventor and Vor Scientific Board Chair Siddhartha Mukherjee, MD, DPhil.
For more information: https://www.vorbiopharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.